Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.

Auteurs : Piccart-Gebhart M, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Naït Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber Rd, Davidson NE, Norton L, Winer EP
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 4120-4129

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.

Auteurs : Paluch-Shimon S, Cherny NI, de Vries EGE, Dafni U, Piccart-Gebhart M, Latino NJ, Cardoso F
Année : 2020
Journal : ESMO Open
Volume : 5

Management of early breast cancer in patients bearing germline BRCA mutations.

Auteurs : Tkint de Roodenbeke D, Pondé N, Buisseret L, Piccart-Gebhart M
Année : 2020
Journal : Semin Oncol
Volume : 47
Pages : 243-248

De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or Not to Boost?

Auteurs : Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Année : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 108
Pages : 1040-1046

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.

Auteurs : Brandão M, Maurer C, Ziegelmann PK, Pondé NF, Ferreira A, Martel S, Piccart-Gebhart M, de Azambuja E, Debiasi M, Lambertini M
Année : 2020
Journal : ESMO Open
Volume : 5

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Auteurs : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Année : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 1438-1446

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.

Auteurs : Jacob L, Witteveen A, Beumer I, Delahaye L, Wehkamp D, Van den Akker J, Snel M, Chan B, Floore A, Bakx N, Brink G, Poncet C, Bogaerts J, Delorenzi M, Piccart-Gebhart M, Rutgers E, Cardoso F, Speed T, van t Veer L, Glas A
Année : 2020
Journal : Commun Biol
Volume : 3
Pages : 397

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial.

Auteurs : Retèl VP, Byng D, Linn SC, Koffijberg H, Rutgers EJ, Cardoso F, Piccart-Gebhart M, Poncet C, Vant Veer LJ, van Harten WH
Année : 2020
Journal : Eur J Cancer
Volume : 137
Pages : 193-203

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Auteurs : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Année : 2020
Journal : Clin Colorectal Cancer
Volume : 19
Pages : 311-318.e1

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Auteurs : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891

<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.

Auteurs : Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, Robertson JFR, Gradishar W, Piccart-Gebhart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 5172-5177

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Auteurs : Demicheli R, Desmedt C, Retsky M, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Année : 2020
Journal : Breast
Volume : 52
Pages : 64-70

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome.

Auteurs : Venet D, Fimereli D, Rothé F, Boeckx B, Maetens M, Majjaj S, Rouas G, Capra M, Bonizzi G, Contaldo F, Galant C, Piccart-Gebhart M, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Sotiriou C
Année : 2020
Journal : EBioMedicine
Volume : 56
Pages : 102793

Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.

Auteurs : Caballero C, Piccart-Gebhart M
Année : 2020
Journal : Ann Oncol
Volume : 31
Pages : 1083-1084

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Auteurs : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.

Auteurs : Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart-Gebhart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Année : 2020
Journal : Br J Cancer
Volume : 122
Pages : 1453-1460

The legacy of Professor Aron Goldhirsch.

Auteurs : Gelber Rd, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart-Gebhart M, Curigliano G
Année : 2020
Journal : Ann Oncol
Volume : 31
Pages : 671-673

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Auteurs : Delaloge S, Piccart-Gebhart M, Rutgers E, Litière S, van t Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 1186-1197

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.

Auteurs : Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart-Gebhart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, De Braud FG, Iorio MV, Verderio P, Daidone MG
Année : 2020
Journal : Int J Mol Sci
Volume : 21

What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?

Auteurs : Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart-Gebhart M
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 2783-2788